Literature DB >> 36090236

Readmission Rates in Patients With Multiple Sclerosis: A Nationwide Cohort Study.

Akhil Padarti1, Amod Amritphale2, William Kilgo1.   

Abstract

BACKGROUND: Multiple sclerosis (MS) is an inflammatory central nervous system demyelinating disorder resulting in neurologic decline. Patients predominantly have a relapsing and remitting disease course requiring multiple hospitalizations and, occasionally, rehospitalizations. Hospitalization readmission rates are important metrics that have direct financial implications for hospitals and serve as an indicator of disease burden on patients and society. We sought to analyze hospital readmissions of patients with MS and identify the subsequent predictive characteristics/comorbidities for readmission.
METHODS: All hospital admissions due to MS were queried using the 2017 Nationwide Readmissions Database. All patients with nonelective rehospitalization within 30 days of discharge were examined.
RESULTS: The 30-day readmission rate for MS is 10.6% (range, 10.4%-10.8%). Female sex has a protective role in readmission rates, and age has no effect. Comorbidities, including heart failure, acute kidney injury, chronic obstructive pulmonary disease, chronic kidney disease, respiratory failure, substance abuse, diabetes, hypertension, peripheral artery disease, liver failure, anemia, coagulation disorders, cancer, depression, and infections, are predictive of readmissions, whereas sleep apnea is protective. No effect is seen with neurologic blindness, plasma exchange, or intravenous immunoglobulin treatment.
CONCLUSIONS: Several medical comorbidities are predictive of hospital readmission of patients with MS. Most rehospitalizations are due to infectious and neurologic etiologies; thus, targeted interventions may lead to lower readmission rates.
© 2022 Consortium of Multiple Sclerosis Centers.

Entities:  

Keywords:  comorbidities; economic issues; multiple sclerosis; readmission etiologies; relapse management

Year:  2022        PMID: 36090236      PMCID: PMC9461718          DOI: 10.7224/1537-2073.2021-089

Source DB:  PubMed          Journal:  Int J MS Care        ISSN: 1537-2073


  26 in total

1.  Comorbidity is associated with disease activity in MS: Findings from the CombiRx trial.

Authors:  Amber Salter; Kaarina Kowalec; Kathryn C Fitzgerald; Gary Cutter; Ruth Ann Marrie
Journal:  Neurology       Date:  2020-06-17       Impact factor: 9.910

2.  Lower 90-day Hospital Readmission Rates for Esophageal Variceal Bleeding After TIPS: A Nationwide Linked Analysis.

Authors:  Barret Rush; Navjot Deol; Anour Teriyaki; Michael Sey; Vipul Jairath; Keith R Walley; Leo A Celi; Mayur Brahmania
Journal:  J Clin Gastroenterol       Date:  2020-01       Impact factor: 3.062

Review 3.  The cost burden of multiple sclerosis in the United States: a systematic review of the literature.

Authors:  Gabriel Adelman; Stanley G Rane; Kathleen F Villa
Journal:  J Med Econ       Date:  2013-03-07       Impact factor: 2.448

4.  Comparison of nationwide trends in 30-day readmission rates after carotid artery stenting and carotid endarterectomy.

Authors:  Sushruth Edla; Varunsiri Atti; Varun Kumar; Byomesh Tripathi; Saroj Neupane; Nikhil Nalluri; George Abela; Howard Rosman; Rajendra H Mehta
Journal:  J Vasc Surg       Date:  2019-09-26       Impact factor: 4.268

Review 5.  How much is the cost of multiple sclerosis--systematic literature review.

Authors:  Katarzyna Kolasa
Journal:  Przegl Epidemiol       Date:  2013

6.  Cardiovascular Dysfunction in Multiple Sclerosis.

Authors:  Raluca Ileana Mincu; Lucia Stefania Magda; Maria Florescu; Andreea Velcea; Sorina Mihaila; Diana Mihalcea; Bogdan O Popescu; Adela Chiru; Cristina Tiu; Mircea Cinteza; Dragos Vinereanu
Journal:  Maedica (Bucur)       Date:  2015-09

7.  Change in MS-related disability in a population-based cohort: a 10-year follow-up study.

Authors:  S J Pittock; W T Mayr; R L McClelland; N W Jorgensen; S D Weigand; J H Noseworthy; B G Weinshenker; M Rodriguez
Journal:  Neurology       Date:  2004-01-13       Impact factor: 9.910

8.  Multiple sclerosis prevalence in the United States commercially insured population.

Authors:  Piyameth Dilokthornsakul; Robert J Valuck; Kavita V Nair; John R Corboy; Richard R Allen; Jonathan D Campbell
Journal:  Neurology       Date:  2016-02-17       Impact factor: 9.910

Review 9.  Oxidative stress in multiple sclerosis: Central and peripheral mode of action.

Authors:  Kim Ohl; Klaus Tenbrock; Markus Kipp
Journal:  Exp Neurol       Date:  2015-11-26       Impact factor: 5.330

10.  Hospitalization rates and discharge status in multiple sclerosis.

Authors:  Sanober Nusrat; David Levinthal; Klaus Bielefeldt
Journal:  Mult Scler Int       Date:  2013-05-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.